MeSH D000690 - amyotrophic lateral sclerosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Alkem Laboratories | Riluzole | Riluzole | 2016-03-30 | |||
| Amylyx Pharmaceuticals | Phenylbutyrate, Taurursodiol | Relyvrio | 2033-12-24 | 2022-09-29 | ||
| Apotex | Riluzole | Riluzole | 2013-06-18 | |||
| Aquestive Therapeutics | Riluzole | Exservan | 2024-02-20 | 2019-11-22 | ||
| Covis Pharma | Riluzole | Rilutek | 1995-12-12 | |||
| Glenmark Pharmaceuticals | Riluzole | Riluzole | 2013-06-18 | |||
| Impax Laboratories | Riluzole | Riluzole | 2003-01-29 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
54%31/57
Phase 2
42%43/103
Phase 3
8%5/63
Approved: 3Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use